Spectrums of Amyotrophic Lateral Sclerosis. Группа авторов

PROPAGATION OF PROTEIN AGGREGATION IN ALS CONCLUSION ACKNOWLEDGMENTS CONFLICT OF INTEREST COPYRIGHT AND PERMISSION STATEMENT REFERENCES

      15  CHAPTER 7: Evidence for a Growing Involvement of Glia in Amyotrophic Lateral Sclerosis INTRODUCTION NON‐NEURONAL CELLS PLAY IMPORTANT ROLES IN NEURODEGENERATION INCLUDING IN ALS GLIAL ACTIVATION IN ALS MODELS GLIAL INCLUSION FORMATION IN ALS THE ROLE OF GLIAL CELLS IN SOD1 PATHOLOGY MIGHT BE DIFFERENT FROM OTHER FORMS OF ALS CONCLUSION ACKNOWLEDGMENTS CONFLICT OF INTEREST COPYRIGHT AND PERMISSION STATEMENT REFERENCES

      16  CHAPTER 8: Animal Models of ALS – Current and Future Perspectives INTRODUCTION THE CLINICAL MANIFESTATIONS OF ALS CURRENT AND EXPERIMENTAL PHARMACOLOGICAL INTERVENTIONS CAUSATIVE FACTORS IN THE DEVELOPMENT OF ALS ANIMAL MODELS OF ALS FUTURE MODEL DEVELOPMENT ACKNOWLEDGMENTS CONFLICT OF INTEREST COPYRIGHT AND PERMISSION STATEMENT REFERENCES

      17  CHAPTER 9: Clinical Trials in ALS – Current Challenges and Strategies for Future Directions INTRODUCTION CHALLENGES IN ALS CLINICAL TRIALS DISEASE HETEROGENEITY LACK OF ESTABLISHED BIOMARKERS LIMITATIONS OF CONVENTIONAL OUTCOME MEASURES PHASE II TRIAL “PARADOX” PATIENT RECRUITMENT AND RETENTION ASSUMPTIONS FOR LEAD‐IN PHASES NAVIGATING REGULATORY NUANCES FUTURE DIRECTIONS ADVANCES IN DISEASE UNDERSTANDING AND ASSESSMENT NEW APPROACHES TO TRIAL DESIGN EDUCATION PEOPLE MAKE OR BREAK A TRIAL ACKNOWLEDGMENTS CONFLICT OF INTEREST COPYRIGHT AND PERMISSION STATEMENT REFERENCES

      18  CHAPTER 10: Future Priorities and Directions in ALS Research and Treatment INTRODUCTION ETIOLOGICAL HETEROGENEITY OF ALS ALS RISK FACTORS CELLULAR DYSFUNCTION IN ALS ALS AS A “TREATABLE” DISEASE THE IMPORTANCE OF EFFECTIVE BIOMARKERS FUTURE THERAPEUTIC AVENUES FOR A HETEROGENEOUS DISEASE ONGOING CLINICAL TRIALS USING CuATSM CONCLUSIONS AND THE ROAD FORWARD IN ALS RESEARCH AND TREATMENT CONFLICT OF INTEREST COPYRIGHT AND PERMISSION STATEMENT REFERENCES

      19  Index

      20  End User License Agreement

      List of Tables

      1 Chapter 1TABLE 1.1 Spectrum of clinical disease phenotypes associated with genetic var...

      2 Chapter 5TABLE 5.1 Summary of key findings linking ALS and the microbiome.

      3 Chapter 9TABLE 9.1 Common adaptive trial designs.

      List of Illustrations

      1 Chapter 2FIGURE 2.1 Timeline of ALS gene discovery and the rate of genetically explai...

      2 Chapter 3FIGURE 3.1 Risk factors in proposed etiologies for sALS. Susceptibility gene...

      3 Chapter 4FIGURE 4.1 People with lytico (ALS) and bodig (PDC) on Guam. (a) A woman bed...FIGURE 4.2 (a) Decline by birth year in the numbers of newly diagnosed ALS, ...FIGURE 4.3 Pedigrees of four typical, unrelated families of Umatac village i...FIGURE 4.4 Cycad tree (Cycas micronesica K.D. Hill) on Guam.FIGURE 4.5 Venn diagram showing suggested interactions of genes and toxicant...

      4 Chapter 5FIGURE 5.1 Main hypotheses explaining